Re: Modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4.
Ando
Y
Y
Tateishi
T
T
Sekido
Y
Y
Yamamoto
T
T
Satoh
T
T
Hasegawa
Y
Y
Kobayashi
S
S
Katsumata
Y
Y
Shimokata
K
K
Saito
H
H
D044466:Asian People / Q000235:genetics; D002121:Calcium Channel Blockers / Q000378:metabolism; D051544:Cytochrome P-450 CYP3A; D003577:Cytochrome P-450 Enzyme System / Q000096:biosynthesis / Q000235:genetics*; D004790:Enzyme Induction; D005838:Genotype; D006801:Humans; D008297:Male; D008862:Microsomes, Liver / Q000201:enzymology; D006899:Mixed Function Oxygenases / Q000096:biosynthesis / Q000235:genetics*; D009543:Nifedipine / Q000378:metabolism; D010084:Oxidation-Reduction; D011110:Polymorphism, Genetic; D012150:Polymorphism, Restriction Fragment Length; D011471:Prostatic Neoplasms / Q000201:enzymology* / Q000208:ethnology / Q000235:genetics*; D044465:White People / Q000235:genetics
D002121:Calcium Channel Blockers; D003577:Cytochrome P-450 Enzyme System; D006899:Mixed Function Oxygenases; C104464:CYP3A protein, human; D051544:Cytochrome P-450 CYP3A; C510163:CYP3A4 protein, human; D009543:Nifedipine